Alteplase and tenecteplase: Applications in the peripheral circulation

Techniques in Vascular and Interventional Radiology

Volumn 4, Issue 2, 2001, Pages 99-106

  Semba, Charles P ^a   Sugimoto, Koji ^a,b   Razavi, Mahmood K ^a,b  

^a GENENTECH INC   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRIN; HEPARIN; LANOTEPLASE; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR; PROLYSE; PROUROKINASE; RETEPLASE; STREPTOKINASE; TENECTEPLASE; UROKINASE;

ACUTE HEART INFARCTION; ARTICLE; BLEEDING; BOLUS INJECTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GENETIC ENGINEERING; HUMAN; INTERVENTIONAL RADIOLOGY; LUNG EMBOLISM; PERIPHERAL CIRCULATION; PERIPHERAL VASCULAR DISEASE; PRACTICE GUIDELINE;

EID: 0034923025     PISSN: 10892516     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-2516(01)90003-4     Document Type: Article

References (40)

1. Surgery versus thrombolytic therapy in the management of peripheral arterial occlusions
2. Iliofemoral deep venous thrombosis: Aggressive therapy with catheter-directed thrombolysis
3. Pulse-spray pharmacomechanical thrombolysis: Preliminary clinical results
4. Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: A double-blinded, randomized trial
5. Bleeding associated with intrathrombus infusions of t-PA for peripheral arterial and venous occlusions
6. Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis
7. Alteplase as an alternative to urokinase
8. Recombinant tissue plasminogen activator
9. The fibrinolytic system: Implications for thrombolytic therapy
10. On the kinetics of the reaction between human antiplasmin and plasmin
11. Thrombolytic therapy using alteplase (rt-PA) in peripheral arterial occlusive disease: Review of the clinical literature
12. Thrombolysis of peripheral arterial bypass grafts: Surgical thrombectomy compared with thrombolysis. A preliminary report
13. Low doses of recombinant human tissue-type plasminogen activator for local thrombolysis in peripheral arteries
14. Recombinant human tissue-type plasminogen activator for thrombolysis in peripheral arteries and bypass grafts
15. Local thrombolytic therapy of acute peripheral arterial ischaemia with tissue plasminogen activator: A dose-ranging study
16. Femoro-popliteal artery thrombolysis with intra-arterial infusion of recombinant tissue-type activator: Report of a pilot trial
17. Vascular surgical society of Great Britain and Ireland: Avoiding the complications of thrombolysis
18. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity: STILE trial
19. A simplified procedure for intra-arterial thrombolysis with tissue-type plasminogen activator in peripheral arterial occlusive disease: Primary and long-term results
20. Bioactivity of cryopreserved alteplase solutions
21. Stability and sterility of recombinant tissue plasminogen activator at -30°C
22. Stability and activity of alteplase with injectable drugs commonly used in cardiac therapy
23. The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared to urokinase for catheter-directed thrombolysis of arterial and venous occlusions
24. Investigational use of tissue plasminogen activator (t-PA) for occluded central venous catheters
25. Double-blind placebo controlled trial of recombinant tissue plasminogen activator for restoration of function in occluded central venous access devices
26. Third-generation thrombolytic drugs
27. A variant of t-PA T103N, KHRR296-299 AAAA that, by bolus, has increased potency and decreased systemic activation of plasminogen
28. A faster acting and more potent form of tissue plasminogen activator
29. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog
30. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double blind randomized trial
31. Platelet function during and after thrombolytic therapy for acute myocardial infarction with reteplase, alteplase, or streptokinase
32. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized control trial. Prolyse in Acute Cerebral Thromboembolism
33. The effects of tissue plasminogen activator, streptokinase, or both on coronary patency, ventricular function, and survival after myocardial infarction
34. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant tissue plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction
35. A comparison of reteplase with alteplase for acute myocardial infarction
36. A modified human tissue plasminogen activator with extended half-life in vivo
37. Long-term comparison of lanoteplase and alteplase for ST elevation myocardial infarction: 6-month follow-up in the InTIME II trial